COVID-19 pandemic as reflected in Advances in Clinical and Experimental Medicine

Abstract

The editorial demonstrates changes in the number and subject matter of papers dealing with issues related to the coronavirus disease 2019 (COVID-19), which were published in Advances in Clinical and Experimental Medicine(ACEM) during 3 years of the pandemic (2020–2022). In 2020, 24 such manuscripts were submitted to the editorial office, of which 9 were published; in 2021, 48 were submitted and 10 published, while in 2022, there were 34 articles submitted and 4 published. Authors of this editorial point out that while initially chances for publication of papers regarding COVID-19 were greater than papers covering other issues, the editors of ACEM gradually enforced the same requirements for COVID-19-related papers as for the others (the acceptance rate for these papers was 37.5% in 2020, 20.8% in 2021 and 11.8% in 2022). The published papers described, among other aspects, the relationship between COVID-19 and other diseases (e.g., pneumonia, Parkinson’s disease and acute kidney injury) and methods of preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among healthcare staff. An emergency situation of pandemic called for disseminating the results of scientific research as promptly as possible; however, the proper answer to this challenge is not lowering and simplifying requirements for peer review, but releasing the results in a form of registered preprints, which allow for provisionally making the paper available for the scientific community while the peer review verification is still ongoing.